

ASX Release

Genepharma Australasia Limited Announces appointment of Director

19th February, 2007 Melbourne: Genepharma Australasia Limited (ASX:GAA) has pleasure in announcing the appointment of non-executive director Mr Warren J. Jenkins.

Mr Jenkins has over 30 years experience in the global pharmaceutical industry having held senior executive positions at Smith Kline and Eli Lilly before joining Serono to build its regional Asia-Pacific sales and marketing operations as Regional Vice President, Oceania and Japan - residing in Japan for four years.

Most recently Mr. Jenkins held the position of Vice-President Sales and Marketing Europe & International for Serono residing in the United Kingdom. Serono, which was recently acquired by Merck KgaA, is a global biotechnology leader with over 4,750 employees and worldwide revenues in 2005 of over USD 2,500 million.

The appointment of Mr Jenkins, an independent non-executive director, increases the number of Genepharma Australasia directors to five consisting of two executive and three independent, non-executive directors:

Mr T.J.R. O'Brien	Independent, non-executive Chairman
Mr D. Bastas	Director and Chief Executive Officer
Mr G.R. Harding	Director and Chief Financial Officer
Mr A.N. Vigopoulos	Independent, non-executive Director
Mr W.J. Jenkins	Independent, non-executive Director

Inquiries:

Dennis Bastas
Genepharma Australasia
03 9699 2300